Navigation Links
Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers

- Company Planning to Initiate Phase 2 Trials in Colorectal Cancer and in Hormone-Refractory Prostate Cancer in Q307 -

SOUTH SAN FRANCISCO, Calif., June 01, 2007 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, today announced promising results from an interim safety analysis of two Phase 1 dose-escalating trials of picoplatin, a new generation platinum for the potential first-line treatment of metastatic colorectal cancer (CRC) and metastatic hormone-refractory prostate cancer (HRPC). Initial safety data from the Phase 1 trial in CRC demonstrated that picoplatin can be safely administered with fluorouracil and leucovorin, and initial safety data from the Phase 1 trial in HRPC demonstrated that picoplatin can be safely combined with the dose of docetaxel (Taxotere(R)) used in current practice for HRPC.

The data were included in abstracts published in the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting Proceedings.

    -- Abstract #14510. Gladkov Jr O, Manikhas G, Biakhov M, Tjulandin S,

       Karlin D. Phase 1 study of picoplatin in combination with 5-

       fluorouracil and leucovorin as initial therapy in subjects with

       metastatic colorectal cancer.

    -- Abstract #15546. Roman L, Karlov P, Kaprin A, Gladkov Jr O, Breitz H.

       Phase 1 study of picoplatin and docetaxel with prednisone in patients

       with chemotherapy-naïve metastatic hormone refractory prostate cancer.


"Our new data indicate that picoplatin can be safely combined with established cancer therapeutics. In 66 patients treated up to 10 months, we have observed reversible myelosuppression that is non-cumulative and has not led to any treatment-related mortality," said Jerry McMahon, Ph.D., chairman and CEO of Poniard. "These Phase 1 studies have explored different doses of picoplatin and different dosing schedu
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Poniard Pharmaceuticals Announces Clinical Data from Picoplatin Phase 2 Small Cell Lung Cancer Trial To Be Presented at American Society of Clinical Oncology Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:9/17/2014)... and SAN JOSE, Calif. , Sept. 17, ... named as a laureate of The Tech Awards 2014, ... to benefit humanity and spark global change. The Tech Awards, ... presented by Applied Materials, Inc., selected Gradian as one of ... Photo - http://photos.prnewswire.com/prnh/20140917/146680 Gradian equips ...
(Date:9/17/2014)... India , September 17, 2014 ... antagonist, GRC 17536, has shown positive data in a ... painful diabetic neuropathy , Glenmark ... Receptor Potential Ankyrin 1 (TRPA1) antagonist, GRC 17536 has ... placebo controlled, multi-centre, proof of concept study conducted on ...
(Date:9/17/2014)... YORK , Sept. 17, 2014  Millions of people ... cervical disc disease. Recently the FDA approved ... cervical disc, an innovative implant device developed by Spinal Kinetics, ... resulting in neck and or arm pain. Hospital for Special ... is the only hospital in New York City ...
Breaking Medicine Technology:Gradian Health Systems Named A 2014 Laureate of The Tech Awards 2Gradian Health Systems Named A 2014 Laureate of The Tech Awards 3Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 3Cervical Disc Clinical Trial for People with Neck and Arm Pain Set to Begin at Hospital for Special Surgery 2
... SweetSpot Diabetes Care, Inc. announced today it has ... Drug Administration (FDA) for the SweetSpot Diabetes Data Management ... understand and use blood glucose meter data to diagnose ... many patients and health care providers to develop this ...
... , Inc. (OTC: HEWA), a leading VIPPS-accredited, ... pre-order program to enable consumers immediate access to Atorvastatin ( ... the medication at up to 50 percent less than ... "We will be one of the earliest and most ...
Cached Medicine Technology:SweetSpot Diabetes Care Receives FDA 510(k) Clearance for SweetSpot Diabetes Data Management Service 2HealthWarehouse.com Offers Lowest Price Generic Lipitor on the Market 2HealthWarehouse.com Offers Lowest Price Generic Lipitor on the Market 3
(Date:9/17/2014)... Thomas A. Sellers, Ph.D., M.P.H., Jong Park, Ph.D. and Hui-Yi ... that influence the risk for developing prostate cancer, according to ... , Prostate cancer is the most common non-skin cancer in ... with the disease in his lifetime. Family history is the ... brother or father with prostate cancer is twice as likely ...
(Date:9/17/2014)... People with facial paralysis are perceived as being ... universal language of facial expression, a new study from ... The findings highlight the important role the face plays ... prejudice against those with facial paralysis because of their ... in the College of Liberal Arts at Oregon State ...
(Date:9/17/2014)... Tools4ever, the market leader ... and Boston Software Systems, leader in healthcare ... Under the agreement, Tools4ever will use ... within its identity and password management solutions. ... automation platforms that streamline complex processes and ...
(Date:9/17/2014)... September 17, 2014. Kessler Foundation is the recipient ... the International Progressive Multiple Sclerosis (MS) Alliance. ... Traumatic Brain Injury Research, is principal investigator of ... of cognitive rehabilitation in individuals with progressive multiple ... grants awarded by the Alliance to investigators in ...
(Date:9/17/2014)... Gerontological Society of America (GSA) invites all journalists ... the country,s largest interdisciplinary conference in the field ... Washington, DC. Media representatives may register free of charge. ... the five-day gathering at the Walter E. Washington Convention ... 2014 is "Making Connections: From Cells to Societies" and ...
Breaking Medicine News(10 mins):Health News:Lack of facial expression leads to perceptions of unhappiness, new OSU research shows 2Health News:Lack of facial expression leads to perceptions of unhappiness, new OSU research shows 3Health News:Tools4ever Partners with Boston Software Systems to Automate Identity and Password Management 2Health News:Tools4ever Partners with Boston Software Systems to Automate Identity and Password Management 3Health News:Tools4ever Partners with Boston Software Systems to Automate Identity and Password Management 4Health News:Kessler Foundation receives first-round grant from International Progressive Multiple Sclerosis Alliance 2Health News:Join GSA in Washington, DC, for the Nation's Premier Aging Conference 2
... ... Innovation and Growth , ... (PRWEB) June 21, 2010 -- DKI Direct ( http://www.dkidirect.com ), a leading Patient ... Chief Marketing Officer. Lewis will lead and build the marketing efforts for both existing ...
... viral for bacterial infections, review found , MONDAY, ... one who can,t always tell if your child has ... for antibiotics: Pediatricians say this is the most common ... Other common missed or mistaken diagnoses include those involving ...
... and cost-effective when targeted to high-risk patients, according ... the official journal of the American Gastroenterological Association ... be excessively costly or even harmful. "Surveillance ... that has the potential to decrease the burden ...
... something is due to our genes and how much is ... academic journal Addiction shows that the case is ... drugs, for two related reasons. First, a young woman ... to choose friends who smoke, drink, or use drugs, thereby ...
... in the journal Addiction reveals that drunkenness increases ... a strong inclination to suppress anger. The two ... reduces the risk of drawing erroneous conclusions about cause and ... of evidence suggesting that drinking may in fact inflict physical ...
... ... because of a small number of adverse event reports received by the FDA from users ... and its safety if used as directed. , ... (PRWEB) June 21, 2010 -- EphedrineHydrochloride.com is pleased to announce ...
Cached Medicine News:Health News:DKI Direct Appoints Greg Lewis as Chief Marketing Officer 2Health News:More Than Half of Pediatricians Make Diagnostic Errors: Survey 2Health News:More Than Half of Pediatricians Make Diagnostic Errors: Survey 3Health News:Surveillance colonoscopy should be targeted to high-risk patients 2Health News:New research shows peer drug use may increase an individual's genetic tendency to use drugs 2Health News:Ephedrine Hydrochloride.com Launches Review Site Examining Ephedrine HCL & Ephedra Based Diet Pills 2
... immunoassay(EIA) test system for the detecton ... Sm, RNP, SSA, SSB, Scl-70 and ... from this assay can be used ... of autoimmune disease. This product is ...
... Multiparameter Kit is designed for ... of the most common autoantibodies. ... quality control system. The built-in ... in each strip gives the ...
... were designed with the proper sensitivity and ... diagnosis of autoimmune disease. Sera from over ... normal individuals were tested during the development ... Concepts compared the results to reference methods ...
... The assay uses highly pure, functional human C1q ... complexes (CIC). In the first stage, CIC in ... controls and standards are dispensed into the C1q ... removed in a washing step and a ready ...
Medicine Products: